New drug duo tested for Tough-to-Treat liver cancer
NCT ID NCT03463876
Summary
This study tested whether combining two drugs, SHR-1210 (an immunotherapy) and apatinib (a targeted therapy), could help control advanced liver cancer. It involved 190 patients whose cancer had worsened or who could not tolerate the standard treatment. The goal was to see if this combination could shrink tumors and extend life for people with limited options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Beijing, Beijing Municipality, 100071, China
Conditions
Explore the condition pages connected to this study.